$GOSS
Gossamer Bio, Inc. Stock $goss

$goss Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000172811723000049 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.476M	$9.632M	$12.00M
YoY Change	-15.97%	-19.74%	5.74%
% of Gross Profit
Research & Development	$36.31M	$37.80M	$42.32M
YoY Change	-14.73%	-10.7%	1.18%
% of Gross Profit
Depreciation & Amortization	$500.0K	$500.0K	$500.0K
YoY Change	8.7%	0.0%	25.0%
% of Gross Profit
Operating Expenses	$46.30M	$47.94M	$54.34M
YoY Change	-14.03%	-11.78%	2.14%
Operating Profit	-$46.30M	-$47.94M	-$54.34M
YoY Change	-14.06%	-11.78%	2.14%
Interest Expense	$3.429M	$3.500M	$3.467M
YoY Change	-207.8%	0.95%	-27.47%
% of Operating Profit
Other Income/Expense, Net	$3.804M	-$1.223M	-$3.442M
YoY Change	548.04%	-64.47%	-22.44%
Pretax Income	-$42.50M	-$49.17M	-$57.79M
YoY Change	-24.74%	-14.92%	0.25%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$42.50M	-$49.17M	-$57.79M
YoY Change	-24.74%	-14.92%	0.25%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.45	-$0.52	-$0.76
Diluted Earnings Per Share	-$0.45	-$0.52	-$0.76
COMMON SHARES
Basic Shares Outstanding	95.44M shares	94.98M shares	75.89M shares
Diluted Shares Outstanding	95.45M shares	94.87M shares	75.89M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$162.1M	$201.9M	$271.6M
YoY Change	-27.02%	-25.69%	-40.08%
Cash & Equivalents	$37.00M	$65.24M	$138.9M
Short-Term Investments	$125.1M	$136.6M	$132.7M
Other Short-Term Assets	$11.25M	$8.557M	$9.151M
YoY Change	6.93%	-6.49%	-27.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$173.4M	$210.4M	$280.8M
YoY Change	-25.49%	-25.06%	-39.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.054M	$3.516M	$5.025M
YoY Change	-74.35%	-30.03%	-15.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$770.0K	$743.0K	$1.019M
YoY Change	-38.6%	-27.09%	0.89%
Total Long-Term Assets	$8.370M	$9.493M	$13.91M
YoY Change	-36.41%	-31.73%	-16.35%
TOTAL ASSETS
Total Short-Term Assets	$173.4M	$210.4M	$280.8M
Total Long-Term Assets	$8.370M	$9.493M	$13.91M
Total Assets	$181.7M	$219.9M	$294.7M
YoY Change	-26.07%	-25.37%	-38.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.205M	$2.731M	$592.0K
YoY Change	-43.58%	361.32%	-44.83%
Accrued Expenses	$14.26M	$14.70M	$17.02M
YoY Change	-50.64%	-13.6%	0.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.61M	$11.61M	$0.00
YoY Change	0.0%
Total Short-Term Liabilities	$40.14M	$40.57M	$34.57M
YoY Change	-9.61%	17.37%	17.4%
LONG-TERM LIABILITIES
Long-Term Debt	$6.436M	$9.221M	$29.17M
YoY Change	-96.98%	-68.39%	1.19%
Other Long-Term Liabilities	$1.826M	$2.645M	$5.706M
YoY Change	-63.23%	-53.65%	-18.49%
Total Long-Term Liabilities	$6.436M	$9.221M	$29.17M
YoY Change	-97.05%	-68.39%	1.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.14M	$40.57M	$34.57M
Total Long-Term Liabilities	$6.436M	$9.221M	$29.17M
Total Liabilities	$244.5M	$248.4M	$264.5M
YoY Change	-6.77%	-6.11%	25.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.124B	-$1.081B	-$860.6M
YoY Change		25.66%	35.48%
Common Stock	$1.062B	$1.053B	$891.1M
YoY Change		18.21%	-1.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$62.80M	-$28.46M	$30.16M
YoY Change
Total Liabilities & Shareholders Equity	$181.7M	$219.9M	$294.7M
YoY Change	-26.07%	-25.37%	-38.92%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$42.50M	-$49.17M	-$57.79M
YoY Change	-24.74%	-14.92%	0.25%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$500.0K
YoY Change	8.7%	0.0%	25.0%
Cash From Operating Activities	-$38.25M	-$52.99M	-$53.48M
YoY Change	-21.65%	-0.92%	-9.19%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$157.0K
YoY Change	-100.0%	-100.0%	-80.42%
Acquisitions
YoY Change
Other Investing Activities	$12.94M	$8.722M	$8.577M
YoY Change	169.56%	1.69%	-32.83%
Cash From Investing Activities	$12.94M	$8.722M	$8.420M
YoY Change	176.47%	3.59%	-29.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$2.903M	$0.00
YoY Change
Cash From Financing Activities	-2.904M	-$2.536M	$721.0K
YoY Change	-13928.57%	-451.73%	-6.85%
NET CHANGE
Cash From Operating Activities	-38.25M	-$52.99M	-$53.48M
Cash From Investing Activities	12.94M	$8.722M	$8.420M
Cash From Financing Activities	-2.904M	-$2.536M	$721.0K
Net Change In Cash	-28.22M	-$46.73M	-$44.50M
YoY Change	-36.04%	5.02%	-4.1%
FREE CASH FLOW
Cash From Operating Activities	-$38.25M	-$52.99M	-$53.48M
Capital Expenditures	$0.00	$0.00	$157.0K
Free Cash Flow	-$38.25M	-$52.99M	-$53.64M
YoY Change	-21.46%	-1.21%	-10.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	55227	shares
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001728117
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38796
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	GOSSAMER BIO, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5461709
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3013 Science Park Road
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	684-1300
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	GOSS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95444095	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65242000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111973000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	136614000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	143705000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8557000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6202000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	210413000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	261880000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3516000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3981000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5234000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5909000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	743000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	680000	usd
CY2023Q1	us-gaap	Assets Assets	219906000	usd
CY2022Q4	us-gaap	Assets Assets	272450000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2731000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1459000	usd
CY2023Q1	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	11523000	usd
CY2022Q4	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	15626000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	11613000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11613000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14704000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20532000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	40571000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49230000	usd
CY2023Q1	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	195925000	usd
CY2022Q4	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	195709000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9221000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11988000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2645000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3446000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	248362000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	260373000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95444096	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95444096	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94478405	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94423181	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1053358000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1044864000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1081388000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1032223000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-436000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-574000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-28456000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12077000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	219906000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	272450000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	37795000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	42322000	usd
CY2023Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	15000	usd
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	20000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10132000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12001000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	47942000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	54343000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-47942000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-54343000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	587000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	224000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3500000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3467000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1690000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-199000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1223000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3442000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-49165000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-57785000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	23000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	115000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-377000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	138000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-385000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49027000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58170000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94870293	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94870293	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75894692	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75894692	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12077000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8127000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	367000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-49165000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	138000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-28456000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121463000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	126000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10983000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	595000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-57785000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-385000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30159000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-49165000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-57785000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	465000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	452000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8127000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10983000	usd
CY2023Q1	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	15000	usd
CY2022Q1	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	20000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	675000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	645000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	352000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	292000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1531000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-125000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2355000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2589000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	63000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-61000	usd
CY2023Q1	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	723000	usd
CY2022Q1	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	683000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1223000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2507000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-273000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	52000	usd
CY2023Q1	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-4103000	usd
CY2022Q1	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	753000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-8117000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5802000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2484000	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2500000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52989000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53483000	usd
CY2023Q1	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	15000	usd
CY2022Q1	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	20000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	76863000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	37403000	usd
CY2023Q1	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	85600000	usd
CY2022Q1	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	46000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	157000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8722000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8420000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	367000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	595000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	126000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2903000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2536000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	721000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	72000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-154000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46731000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44496000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111973000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183467000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65242000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138971000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	663000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	675000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3029000	usd
CY2023Q1	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	115000	usd
CY2022Q1	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	-377000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1081400000	usd
	goss	Funds Raised Through Preferred Equity Financing Convertible Note Financings And Completed Initial Public Offering FundsRaisedThroughPreferredEquityFinancingConvertibleNoteFinancingsAndCompletedInitialPublicOffering	1062100000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34548153	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28058796	shares
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10092000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10093000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6576000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6112000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3516000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3981000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5417000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13534000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3060000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2983000	usd
CY2023Q1	goss	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	1137000	usd
CY2022Q4	goss	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	1104000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3549000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1065000	usd
CY2023Q1	goss	Accrued Legal Fees Current AccruedLegalFeesCurrent	390000	usd
CY2022Q4	goss	Accrued Legal Fees Current AccruedLegalFeesCurrent	380000	usd
CY2023Q1	goss	Accrued Accounting Fees Current AccruedAccountingFeesCurrent	185000	usd
CY2022Q4	goss	Accrued Accounting Fees Current AccruedAccountingFeesCurrent	521000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	966000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	945000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14704000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20532000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	136622000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	26000	usd
CY2023Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	0	shares
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	34000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	136614000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12	security
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	143829000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	137000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	143705000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	16	security
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	4200000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	31500000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	136614000	usd
CY2023Q1	goss	Available For Sale Securities Debt Maturities After One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	136614000	usd
CY2023Q1	goss	Common Stock Voting Rights Number Of Votes Per Share CommonStockVotingRightsNumberOfVotesPerShare	1	vote
CY2023Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17487165	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.24
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	47000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4620560	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.22
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	425808	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.34
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21681917	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.54
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	227000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	21681917	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.54
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	227000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	8140578	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	12.19
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8127000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10983000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	778000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	761000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	791000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	771000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2492000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3419000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	144000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6055000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	350000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5705000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3060000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2645000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5705000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	900000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	900000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
goss-20230331_cal.xml	Edgar Link	unprocessable
goss-20230331_def.xml	Edgar Link	unprocessable
0001728117-23-000049-index-headers.html	Edgar Link	pending
0001728117-23-000049-index.html	Edgar Link	pending
0001728117-23-000049.txt	Edgar Link	pending
0001728117-23-000049-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
goss-20230331.htm	Edgar Link	pending
goss-20230331.xsd	Edgar Link	pending
goss-20230331x10qxexx311.htm	Edgar Link	pending
goss-20230331x10qxexx312.htm	Edgar Link	pending
goss-20230331x10qxexx321.htm	Edgar Link	pending
goss-20230331x10qxexx322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
goss-20230331_lab.xml	Edgar Link	unprocessable
goss-20230331_pre.xml	Edgar Link	unprocessable
goss-20230331_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOSS
Gossamer Bio, Inc. Stock $goss

2023 Q2 Form 10-Q Financial Statement

#000172811723000049 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS Gossamer Bio, Inc. Stock $goss

2023 Q2 Form 10-Q Financial Statement

#000172811723000049 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS
Gossamer Bio, Inc. Stock $goss